Skip to main content

Advertisement

Table 2 Health insurance characteristics

From: Impact of 5-HT3 receptor antagonists on chemotherapy-induced nausea and vomiting: a retrospective cohort study

  Breast cancer Carboplatin-treated lung cancer Cisplatin-treated lung cancer
  All Older 5-HT3RAs Palonosetron P All Older 5-HT3RAs Palonosetron P All Older 5-HT3RAs Palonosetron P
N 3,606 1,742 1,864   4,497 2,691 1,806   1,154 764 390  
Type of payer (%)     NS     NS     NS
Commercial 3,321 (92.1) 1,592 (91.4) 1,729 (92.8)   3,632 (80.8) 2,149 (79.9) 1,483 (82.1)   971 (84.1) 638 (83.5) 333 (85.4)  
Public 167 (4.6) 87 (5.0) 80 (4.3)   715 (15.9) 448 (16.7) 267 (14.8)   121 (10.5) 81 (10.6) 40 (10.3)  
Self-insured 100 (2.8) 54 (3.1) 46 (2.5)   134 (3.0) 84 (3.1) 50 (2.8)   55 (4.8) 39 (5.1) 16 (4.1)  
Unknown 18 (0.5) 9 (0.5) 9 (0.5)   16 (0.4) 10 (0.4) 6 (0.3)   7 (0.6) 6 (0.8) 1 (0.3)  
Type of plan (%)     <0.0001     <0.0001     NS
HMO 813 (22.6) 434 (24.9) 379 (20.3)   1,071 (23.8) 734 (27.3) 337 (18.7)   272 (23.6) 182 (23.8) 90 (23.1)  
Indemnity 320 (8.9) 136 (7.8) 184 (9.9)   854 (19.0) 499 (18.5) 355 (19.7)   170 (14.7) 112 (14.7) 58 (14.9)  
PPO 1,742 (48.3) 792 (45.5) 950 (51.0)   1,982 (44.1) 1,114 (41.4) 868 (48.1)   551 (47.8) 360 (47.1) 191 (49.0)  
POS 556 (15.4) 316 (18.1) 240 (12.9)   462 (10.3) 278 (10.3) 184 (10.2)   120 (10.4) 77 (10.1) 43 (11.0)  
Other 175 (4.9) 64 (3.7) 111 (6.0)   128 (2.9) 66 (2.5) 62 (3.4)   41 (3.6) 33 (4.3) 8 (2.1)  
Pharmacy benefit (%)     0.0008     <0.0001     NS
No 700 (19.4) 300 (17.2) 400 (21.5)   1,229 (27.3) 656 (24.4) 573 (31.7)   246 (21.3) 151 (19.8) 95 (24.4)  
Yes 2,372 (65.8) 1,198 (68.8) 1,174 (63.0)   2,809 (62.5) 1,769 (65.7) 1,040 (57.6)   761 (65.9) 518 (67.8) 243 (62.3)  
Unknown 534 (14.8) 244 (14.0) 290 (15.6)   459 (10.2) 266 (9.9) 193 (10.7)   147 (12.7) 95 (12.4) 52 (13.3)  
  1. HMO: health maintenance organization, PPO: preferred provider organization, POS: point of service, pts: patients.